Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy
Condition(s) studied
Investigational drug(s) / intervention(s)
Fecal Microbiota Transplant (FMT): One course of fecal microbiota transplantation (FMT) was administered in addition to standard therapy.
Standard Therapy: Standard Therapy Alone
Study summary
By 2030, pancreatic cancer is projected to become the second leading cause of cancer-related deaths, with a 5-year survival rate below 10%. Approximately 20% of patients are diagnosed at a borderline resectable or resectable stage, and surgical resection remains the only curative option. However, total pancreatectomy (TP) often leads to severe diarrhea (incidence rate: 43.5%) due to exocrine insufficiency, and current pancreatic enzyme replacement therapy shows limited efficacy in some patients.
Recent studies highlight the critical role of gut microbiota in pancreatic cancer progression and postoperative recovery. Patients with pancreatic ductal adenocarcinoma (PDAC) exhibit a 1000-fold increase in intrapancreatic bacterial load compared to normal tissues, with significantly elevated Bacteroides abundance and reduced Firmicutes and Proteobacteria in fecal samples. Postoperative dysbiosis is linked to complications; for example, diarrhea after cholecystectomy is dominated by Proteobacteria, suggesting that microbial imbalance may underlie diarrhea following TP.
To address this, the study proposes fecal microbiota transplantation (FMT) via oral capsules. FMT has proven effective in treating recurrent Clostridium difficile infection by restoring healthy microbiota. This research will systematically evaluate the efficacy and safety of FMT in alleviating post-TP diarrhea through clinical indicators and 16S rDNA sequencing, offering novel insights into postoperative management of pancreatic cancer.
Eligibility
Primary outcome measure(s)
- Diarrhea HART Score — Assessed every two cycles up to 24 weeks (each cycle is 21 days)
The Hart Diarrhea Scoring Scale assigns scores to nine categories. The total score is the sum of scores from each bowel movement on the same day, with each movement evaluated using this scale. A cumulative score of ≥12 points within 24 hours is classified as diarrhea.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang | Hangzhou | Zhejiang |
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06960122 on ClinicalTrials.gov ↗ ← All trials in China